Get 50% OFF This Summer!
Ishita Drugs & Industries
No Data Available
No Stocks
Unlock Smart Score
See Detailed Analysis & Insights
Unlock Insights
See Detailed Analysis & Insights
No Research Report
ROE
Avg ROE (3 Yrs) : NaN%
ROCE
Avg ROCE (3 Yrs) : NaN%
ROA
Avg ROA (3 Yrs) : NaN%
NPM
Avg NPM (3 Yrs) : NaN%
No Data Available
Unlock Management Data
See Detailed Analysis & Insights
Ishita Drugs & Industries Limited was incorporated in Feb.'92 by Jagdish Agarwal. The Company is engaged in the manufacture of various Activa Pharma Ingredients, drug intermediates, fine chemicals and excipient. It has a state-of-art manufacturing facility, in terms of reaction capabilities, quality control and environmental safety. The plant has been designed and constructed to meet GMP norms.
The genesis of the Ishita Group in 1992 was the result of the entrepreneurial spirit of Mr. Jagdish Agrawal, who set up a reactive dye manufacturing unit in Ahmedabad. Buoyed by the growth of its first Venture, the Group made its maiden foray in the pharma sector in 1981 by setting up a small Bulk drugs plant at Surendranagar in Gujarat, to cater to the need of Pharma industry for Quality Products. The Bulk Drugs Industry at that point of time was highly dependent on costly imports and the growth was not achievable. The Company gradually formed a vertically integrated industry chain covering Drug Intermediates, Active Pharma Ingredients (APIs), excipients and finished dosage forms. The Group has 3 manufacturing facilities located in Gujarat, 2 for APIs and drug intermediates (at Ahmedabad and Surendranagar) and 1 for finished pharmaceutical formulations (at Mehsana).
Thereafter, the Company set up a project to manufacture bulk drugs at Sanand, in the Ahmedabad district of Gujarat with an installed capacity of 408 tpa. Commercial production commenced in Jan.'95. It established an in-house R&D laboratory which has developed a highly improved process technology for norfloxacin, which was implemented in the plant during Oct.'95.
The Company in 2009 undertook a small expansion cum-debottlenecking project; it upgraded many existing equipments.
Ishita Drugs & Industries share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.
Market capitalization of Ishita Drugs & Industries indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Ishita Drugs & Industries is valued compared to its competitors.
Ishita Drugs & Industries PE ratio helps investors understand what is the market value of each stock compared to Ishita Drugs & Industries 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.
The PEG ratio of Ishita Drugs & Industries evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.
Return on Equity (ROE) measures how effectively Ishita Drugs & Industries generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.
Return on Capital Employed (ROCE) evaluates the profitability of Ishita Drugs & Industries in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.
Total debt of Ishita Drugs & Industries shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.
The Debt-to-Equity (DE) ratio of Ishita Drugs & Industries compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.
CAGR shows the consistent growth rate of Ishita Drugs & Industries over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.
Technical analysis of Ishita Drugs & Industries helps investors get an insight into when they can enter or exit the stock. Key components of Ishita Drugs & Industries Technical Analysis include:
There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.
There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Ishita Drugs & Industries shares often struggle to rise above due to selling pressure.
Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Ishita Drugs & Industries ’s financial health and profitability.
Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.
Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.
The financials of Ishita Drugs & Industries provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.
The profit and loss statement of Ishita Drugs & Industries highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Ishita Drugs & Industries .
The balance sheet presents a snapshot of Ishita Drugs & Industries ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.
Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.
Download the App